Neurology Minute

Dr. Tesha Monteith discusses the Neurology article, "Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial" by Richard B. Lipton and colleagues, available in the September 24th issue of Neurology or at neurology.org.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209745

Dr. Rae Bacharach discusses the Neurology Today article, "Large Study Finds COVID Vaccination Does Not Increase Multiple Sclerosis Relapses" by Susan FitzGerald, available in the September 5th issue of Neurology Today or at neurologytoday.com.  Show reference:  https://journals.lww.com/neurotodayonline/fulltext/2024/09050/large_study_finds_covid_vaccination_does_not.3.aspx

In the third episode of this three-part series, Dr. Stacey Clardy and Dr. Mary Schroth discuss the critical objective of advancing the quality of life for individuals with SMA in the coming years. Show reference:  https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200310

Dr. David Perez and Dr. Glenn Nielsen discuss the effectiveness of physiotherapy in treating functional motor disorder and to determine the best approach for physiotherapy treatment.  Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00135-2/fulltext

In the second episode of this three-part series, Dr. Stacey Clardy and Dr. Mary Schroth discuss the currently available treatments for spinal muscular atrophy.  Show reference:  https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200310

In the first episode of this three-part series, Dr. Stacey Clardy and Dr. Mary Schroth discuss the most common types of spinal muscular atrophy. Show reference: https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200310 

In part two of this series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss how this new blood test can enhance the accuracy of diagnosing Alzheimer’s disease in patients with cognitive symptoms. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669  

In the second part of this two-part series, Dr. Jeff Ratliff and Dr. Calum Hamilton discuss the clinical criteria that listeners should look out for, indicating a subtype of mild cognitive impairment known as DLB, which could potentially progress into a full dementia with Lewy body phenotype. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499  

In part one of this two-part series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss the top-line findings from the study exploring the diagnostic performance of blood biomarkers for Alzheimer disease in clinical cohorts. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669   

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Calium discuss the risk of developing dementia among patients with MCI at three or five-year time points. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499   

Dr. Jeff Ratliff talks about the FDA approval of Crexont for the treatment of Parkinson disease.  Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2808496

Dr. Jeff Ratliff discusses an exciting study in the world of deep brain stimulation for Parkinson disease.  Show reference: https://www.nature.com/articles/s41591-024-03196-z

Dr. Tesha Monteith talks about the efficacy of atogepant for the preventive treatment of chronic migraine in participants with and without acute medication overuse. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209584   

Dr. Stacey Clardy and Dr. Nicola de Souza discuss how to improve care in the clinic for these veterans and military service members. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209417

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699 

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss why clinicians should be cautious when relying too much on dopaminergic imaging. Show reference: https://doi.org/10.1212/WNL.0000000000209453 

In part two of this two-part series, Dr. Tesha Monteith discusses the key features of long COVID.   Show reference: https://doi.org/10.17226/27768

In part one of this two-part series, Dr. Tesha Monteith discusses the 2024 National Academies of Sciences, Engineering, and Medicine formal definition of long COVID.  Show reference: https://doi.org/10.17226/27768

Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss the strengths of dopamine transporter imaging or DAT imaging in diagnosing patients with Parkinsonian disorders. Show references: https://doi.org/10.1212/WNL.0000000000209453 

Dr. Dan Ackerman and Dr. Luciano A. Sposato discuss the topic of embolic stroke of undetermined sources and the controversies surrounding cardiac monitoring and anticoagulation. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209535